|
US5023321A
(en)
|
1982-12-13 |
1991-06-11 |
Howard Florey Institute Of Experimental Physiology & Medicine |
Molecular cloning and characterization of a further gene sequence coding for human relaxin
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4682195A
(en)
|
1985-09-30 |
1987-07-21 |
General Electric Company |
Insulated gate device with configured emitter contact pad
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4835251A
(en)
|
1986-06-23 |
1989-05-30 |
Genetech, Inc. |
Method of chain combination
|
|
EP0266032A1
(en)
|
1986-08-29 |
1988-05-04 |
Beecham Group Plc |
Modified fibrinolytic enzyme
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5302523A
(en)
|
1989-06-21 |
1994-04-12 |
Zeneca Limited |
Transformation of plant cells
|
|
US7705215B1
(en)
|
1990-04-17 |
2010-04-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US5550318A
(en)
|
1990-04-17 |
1996-08-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US5322783A
(en)
|
1989-10-17 |
1994-06-21 |
Pioneer Hi-Bred International, Inc. |
Soybean transformation by microparticle bombardment
|
|
US5484956A
(en)
|
1990-01-22 |
1996-01-16 |
Dekalb Genetics Corporation |
Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
|
|
US5466468A
(en)
|
1990-04-03 |
1995-11-14 |
Ciba-Geigy Corporation |
Parenterally administrable liposome formulation comprising synthetic lipids
|
|
US5384253A
(en)
|
1990-12-28 |
1995-01-24 |
Dekalb Genetics Corporation |
Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
US5610042A
(en)
|
1991-10-07 |
1997-03-11 |
Ciba-Geigy Corporation |
Methods for stable transformation of wheat
|
|
DE4204650C1
(enExample)
|
1992-02-15 |
1993-07-08 |
Hoffmeister, Helmut, Dr., 4400 Muenster, De |
|
|
DE69334225D1
(de)
|
1992-07-07 |
2008-07-31 |
Japan Tobacco Inc |
Verfahren zur transformation einer monokotyledon pflanze
|
|
US5702932A
(en)
|
1992-07-20 |
1997-12-30 |
University Of Florida |
Microinjection methods to transform arthropods with exogenous DNA
|
|
WO1994002620A2
(en)
|
1992-07-27 |
1994-02-03 |
Pioneer Hi-Bred International, Inc. |
An improved method of agrobacterium-mediated transformation of cultured soybean cells
|
|
DE4228457A1
(de)
|
1992-08-27 |
1994-04-28 |
Beiersdorf Ag |
Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
|
|
GB9222888D0
(en)
|
1992-10-30 |
1992-12-16 |
British Tech Group |
Tomography
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
JPH08506247A
(ja)
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えｃｔｌａ４ポリペプチドおよびその製造方法
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
ATE397066T1
(de)
|
1993-10-27 |
2008-06-15 |
Univ Columbia |
Methode zur bildung einer subtrahierten cdna bank und ihre verwendung
|
|
US5656610A
(en)
|
1994-06-21 |
1997-08-12 |
University Of Southern California |
Producing a protein in a mammal by injection of a DNA-sequence into the tongue
|
|
FR2722208B1
(fr)
|
1994-07-05 |
1996-10-04 |
Inst Nat Sante Rech Med |
Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5736524A
(en)
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
|
IE80468B1
(en)
|
1995-04-04 |
1998-07-29 |
Elan Corp Plc |
Controlled release biodegradable nanoparticles containing insulin
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US5811395A
(en)
|
1995-06-07 |
1998-09-22 |
Medical University Of South Carolina |
Relaxin analogs and derivatives methods and uses thereof
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5705629A
(en)
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
|
US5780448A
(en)
|
1995-11-07 |
1998-07-14 |
Ottawa Civic Hospital Loeb Research |
DNA-based vaccination of fish
|
|
US5928906A
(en)
|
1996-05-09 |
1999-07-27 |
Sequenom, Inc. |
Process for direct sequencing during template amplification
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US5945100A
(en)
|
1996-07-31 |
1999-08-31 |
Fbp Corporation |
Tumor delivery vehicles
|
|
US5710137A
(en)
*
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
|
CA2263705C
(en)
|
1996-08-19 |
2007-12-04 |
Nancy Smyth-Templeton |
Novel sandwich liposome complexes comprising a biologically active agent
|
|
US5981274A
(en)
|
1996-09-18 |
1999-11-09 |
Tyrrell; D. Lorne J. |
Recombinant hepatitis virus vectors
|
|
US5846225A
(en)
|
1997-02-19 |
1998-12-08 |
Cornell Research Foundation, Inc. |
Gene transfer therapy delivery device and method
|
|
US5736167A
(en)
|
1997-02-27 |
1998-04-07 |
Chang; Hui Hwa |
Mold device for making safety shoe
|
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
|
US5994624A
(en)
|
1997-10-20 |
1999-11-30 |
Cotton Incorporated |
In planta method for the production of transgenic plants
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
HRP20130077A2
(hr)
|
1998-12-23 |
2013-07-31 |
Pfizer Inc. |
Humana monoklonalna protutjela za ctla-4
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
CN102766210B
(zh)
|
1999-08-24 |
2015-07-08 |
E.R.施贵宝&圣斯有限责任公司 |
人ctla-4抗体及其应用
|
|
ATE312189T1
(de)
|
2000-01-21 |
2005-12-15 |
Biovex Ltd |
Virusstämme für die onkolytische behandlung von krebs
|
|
AU2003297499A1
(en)
*
|
2002-12-23 |
2004-07-22 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
KR101444717B1
(ko)
|
2003-07-02 |
2014-09-26 |
노보 노르디스크 에이/에스 |
Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
|
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
WO2005082422A1
(en)
*
|
2004-02-24 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Combination of ad-p53 and chemotherapy for the treatment of tumours
|
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
ES2374603T3
(es)
|
2005-01-06 |
2012-02-20 |
Novo Nordisk A/S |
Agentes de unión a kir y procedimientos de uso de los mismos.
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
CN101300272B
(zh)
|
2005-10-14 |
2013-09-18 |
依奈特制药公司 |
用于治疗增生性病症的组合物和方法
|
|
US20100189723A1
(en)
|
2007-01-11 |
2010-07-29 |
Peter Andreas Nicolai Reumert Wagtmann |
Anti-kir antibodies, formulations, and uses thereof
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
GR1006941B
(el)
|
2009-06-01 |
2010-08-27 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Πεπτιδικη συνθεση (peptide synthesis)
|
|
IN2012DN00863A
(enExample)
|
2009-07-31 |
2015-07-10 |
Medarex Inc |
|
|
CA2772204A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
CA2805643A1
(en)
|
2010-07-16 |
2012-01-19 |
Epeius Biotechnologies Corporation |
Targeted nanoparticles for cancer and other disorders
|
|
UA113280C2
(xx)
|
2010-11-11 |
2017-01-10 |
|
АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
|
|
BR112013012138B1
(pt)
|
2010-11-22 |
2022-02-22 |
Innate Pharma Sa |
Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
|
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
FI3381942T4
(fi)
|
2012-08-30 |
2025-12-16 |
Amgen Inc |
Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
|
|
US20150250837A1
(en)
*
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
EA027277B1
(ru)
|
2012-10-16 |
2017-07-31 |
Альмираль, С.А. |
Производные пирроллотриазинона в качестве ингибиторов pi3k
|
|
CN105407902A
(zh)
|
2013-03-05 |
2016-03-16 |
贝勒医学院 |
溶瘤病毒
|
|
EP2968345B1
(en)
|
2013-03-13 |
2017-12-13 |
The Regents of The University of Michigan |
Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
RU2016107426A
(ru)
|
2013-08-02 |
2017-09-07 |
Адуро Байотек Холдингс, Юроуп Б.В. |
Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
|
|
AU2014308648B2
(en)
|
2013-08-22 |
2020-11-12 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Immuno-oncolytic therapies
|
|
LT3702373T
(lt)
|
2013-09-13 |
2022-11-10 |
Beigene Switzerland Gmbh |
Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
|
|
IL292510A
(en)
*
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
WO2015082376A2
(en)
|
2013-12-03 |
2015-06-11 |
Bayer Pharma Aktiengesellschaft |
Use of pi3k-inhibitors
|
|
GB201405834D0
(en)
|
2014-04-01 |
2014-05-14 |
Univ London Queen Mary |
Oncolytic virus
|
|
US10765710B2
(en)
|
2014-07-16 |
2020-09-08 |
Institut Gustave-Roussy |
Combination of oncolytic virus with immune checkpoint modulators
|
|
CN110381997A
(zh)
*
|
2016-12-12 |
2019-10-25 |
茂体外尔公司 |
用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
|